Silybin B
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Silybin B
Description:
Silybin B (Silibinin B) is an orally active amyloid-β aggregation inhibitor and ATR pathway activator, that can cross the blood-brain barrier. Silybin B inhibits Aβ fibril formation and promotes amorphous aggregate formation, while activating the ATR-mediated DNA damage repair pathway and inhibiting JNK/p38 MAPK signaling. Silybin B can reduce Cisplatin (HY-17394) -induced neuronal DNA damage and apoptosis. Silybin B has anti-oxidative stress, cell cycle regulation and neuroprotective activities. Silybin B is mainly used in the study of Alzheimer's disease and Cisplatin chemotherapy-related neurotoxicity[1][2][3].Product Name Alternative:
Silibinin BUNSPSC:
12352005Hazard Statement:
H302Target:
Amyloid-β; Apoptosis; JNK; p38 MAPKType:
Natural ProductsRelated Pathways:
Apoptosis; MAPK/ERK Pathway; Neuronal SignalingApplications:
Cancer-programmed cell deathField of Research:
Cancer; Neurological DiseaseAssay Protocol:
https://www.medchemexpress.com/silybin-b.htmlConcentration:
10mMPurity:
99.90Solubility:
DMSO : 250 mg/mL (ultrasonic)Smiles:
O=C1[C@H](O)[C@@H](C2=CC=C(O[C@@H](CO)[C@H](C3=CC=C(O)C(OC)=C3)O4)C4=C2)OC5=CC(O)=CC(O)=C15Molecular Formula:
C25H22O10Molecular Weight:
482.44Precautions:
H302References & Citations:
[1]Sciacca MFM, et al. Inhibition of Aβ Amyloid Growth and Toxicity by Silybins: The Crucial Role of Stereochemistry. ACS Chem Neurosci. 2017 Aug 16;8 (8) :1767-1778.|[2]Wang XL, et al. Silybin B exerts protective effect on cisplatin-induced neurotoxicity by alleviating DNA damage and apoptosis. J Ethnopharmacol. 2022 Apr 24;288:114938.|[3]An-Shen Lin, et al. Cancer Preventive Agents. 7. Antitumor-Promoting Effects of Seven Active Flavonolignans from Milk Thistle (Silybum marianum.) on Epstein-Barr Virus Activation, Pharmaceutical Biology, 45:10, 735-738.Shipping Conditions:
Room TemperatureStorage Conditions:
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category:
Natural ProductsClinical Information:
No Development ReportedCAS Number:
[142797-34-0]
